Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest Temozolomide Stories

2013-09-16 12:28:09

Company invites individual and institutional investors to log-on to view presentation NEW YORK, Sept. 16, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that their September 12th RetailInvestorConferences.com presentation is now available for on-demand viewing. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat glioblastoma...

2013-09-09 08:27:39

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK, Sept. 9, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat...

2013-09-03 08:27:46

DelMar Developing VAL-083 in U.S. and China to Treat Aggressive Cancers VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 15(th) Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Monday, September 9(th) at 3:15 p.m. EDT in Room 7.02 at the...

2013-08-06 23:29:05

Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a new vaccine study beginning at North Shore-LIJ ‘s Brain Tumor Center. New York, NY (PRWEB) August 06, 2013 On August 6, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a new vaccine study beginning at North Shore-LIJ’s Brain Tumor Center. According to an August 1, 2013 article published on The Island Now, titled, “Brain...

2013-06-04 08:30:56

BUFFALO, N.Y., June 4, 2013 /PRNewswire/ -- Kinex Pharmaceuticals, Inc. announced today, that the FDA has allowed its Investigational New Drug (IND) application for KX02, Kinex's dual src/pretubulin inhibitor for the glioblastoma setting. KX02 is partnered in the greater China territory with XiangXue Pharmaceuticals (300147.SZ) of Guangzhou, China. KX02 is Kinex's second internally developed compound to enter clinical studies and Phase I clinical protocols are being finalized...

2013-06-03 10:45:11

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center. The study was presented today on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of...

2013-06-03 10:43:06

Gene panel may help personalize therapy for aggressive brain tumors A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center. The results of the study were presented today at the annual meeting of the American Society of Clinical Oncology. This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the...

2013-06-03 08:28:12

Activity with VAL-083 Observed in Recurrent Malignant Glioma and Progressive Secondary Brain Tumors VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company presented a poster entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual...

2013-05-07 23:03:28

Advocates from across the country joined the National Brain Tumor Society in meeting with congressional leaders to discuss the importance of cancer research funding and oral chemotherapy parity. Boston, MA (PRWEB) May 07, 2013 National Brain Tumor Society, the largest nonprofit dedicated to the brain tumor community in the United States, today held their annual “Head to the Hill” advocacy day in Washington, D.C. The event drew hundreds of brain tumor advocates from across the...

2013-05-07 08:32:59

ST. HELIER, Jersey, May 7, 2013 /PRNewswire/ -- Novocure announced today that the EF-14 pivotal clinical trial for patients with newly diagnosed glioblastoma (GBM) brain tumors has enrolled its first patient in Korea. This randomized, controlled trial is designed to enroll approximately 700 patients and will test the efficacy and safety of NovoTTF(TM) Therapy when added to the current best standard of care for newly diagnosed GBM. NovoTTF Therapy is delivered by a portable, non-invasive...